SLU-PP-332dosing chart SLU-PP-332 is a synthetic compound that has garnered significant attention in research circles for its ability to mimic the metabolic effects of exercise at a cellular level. As a potent pan-agonist of estrogen-related receptors (ERRs), particularly ERRα, SLU-PP-332 activates pathways normally triggered by endurance training. This activation leads to increased energy expenditure, enhanced fatty acid oxidation, and a reduction in fat mass accumulation, positioning it as a promising agent for metabolic health research. The peptide's designation as an "exercise in a pill" stems from its capacity to promote mitochondrial function and boost oxidative metabolism in muscle and brown fat, without directly influencing appetite or promoting increased physical activity.
The core mechanism of SLU-PP-332 lies in its interaction with estrogen-related receptors (ERRs). These are a family of nuclear receptors, often referred to as "orphan" receptors because their natural ligands are not fully understood. SLU-PP-332 acts as a potent agonist, meaning it binds to and activates these receptors. While classified as a pan-agonist, its strongest activity is observed at ERRα.作者：H Nasri·2024—SLU-PP-332activates estrogen receptor-related orphan receptors, increasing energy expenditure, fatty acid oxidation, and decreasing fat mass accumulation. By activating ERRα, SLU-PP-332 effectively signals the body to increase its metabolic rate, akin to the physiological changes experienced during strenuous physical activity.2025年8月22日—SLU-PP-332is a potent pan-estrogen receptor-associated receptor agonist used in laboratory research to study metabolic diseases. It enhances ... This includes boosting the production of enzymes involved in energy metabolism and improving the efficiency of cellular energy productionSLU-PP-332: Revolutionize Mitochondrial Health .... The compound has demonstrated notable effects in preclinical models, reducing fat mass and improving glucose metabolism in obese mouse models, underscoring its potential in addressing metabolic syndromeSLU-PP-332is a pan-estrogen receptor-related receptor (ERR) agonist with high affinity for ERRα, ERRβ, and ERRγ, exhibiting EC50 values of 98, 230, ....
SLU-PP-332 is characterized by its specific action on ERR receptors, with reported EC50 values indicating high affinity and potency. For instance, it exhibits an EC50 of 98 nM for ERRα, 230 nM for ERRβ, and 430 nM for ERRγ, making it a selective agonist that primarily targets the ERRα subtypeSLU-PP-332 | ERR pan-agonist/Exercise mimetic. This selectivity is crucial as it allows for targeted metabolic effects while minimizing potential off-target interactions.
The potential applications of SLU-PP-332 are primarily focused on research into metabolic disorders and enhancing physiological functions associated with exercise. These include:
* Metabolic Health: Research suggests SLU-PP-332 can help alleviate symptoms of metabolic syndrome by improving glucose homeostasis and reducing adiposity.
* Fat Oxidation: The peptide enhances the breakdown of fatty acids for energy, contributing to reduced fat accumulation.New hopes on "SLU-PP-332" as an effective agent for ...
* Mitochondrial Function: By improving the function of mitochondria, the powerhouses of cells, SLU-PP-332 supports cellular energy production and overall metabolic efficiencySLU-PP-332is a pan-ERR agonist, meaning it activates all three Estrogen-Related Receptors (ERRα, ERRβ, ERRγ). These receptors aren't related to estrogen ....
* Muscle Activity: Emerging research indicates a potential role in stimulating muscle activity and promoting hyperplasia, the creation of new muscle cells.
Currently, SLU-PP-332 is primarily utilized in molecular and cellular researchSLU-PP-332 | ERR pan-agonist/Exercise mimetic. It is available as a research compound, and its use is strictly limited to laboratory settings for scientific investigationPeptide SLU-PP-332(SLOOP): The Molecule Helping Fight Obesity and Neurodegeneration Disease · Accelerated fat loss · Reduced fat accumulation · Enhanced lean .... While preclinical studies have shown promising results, SLU-PP-332 is not approved for human or veterinary diagnostic or therapeutic use.Support Metabolic Health with SLU-PP-322 | Peptides at Elase The information available often highlights its status as an "experimental research peptide" or "investigational peptide," emphasizing that it is still in the early stages of scientific inquiry. Researchers and institutions are actively exploring its mechanisms and potential benefits, contributing to a growing body of SLU-PP-332 informationSLU-PP-332is a compound which is a potent but non-selective estrogen-related receptor (ERR) agonist, acting most strongly at ERRα with an EC50 of 98 nM..
Given its status as a research chemical, specific human dosage guidelines for SLU-PP-332 are not established. Information regarding dosing charts or protocols found online typically pertains to experimental settings or is provided by research chemical suppliersSupport Metabolic Health with SLU-PP-322 | Peptides at Elase. It is crucial to understand that any product labeled SLU-PP-332 is intended for research purposes only and should not be administered to humans or animals. The safety profile and potential side effects in humans are not yet fully understood, and any use outside of controlled laboratory research carries significant risks2025年8月12日—SLU-PP-332mimics exercise at the cellular level, upgrading oxidative metabolism in muscle and brown fat. Tesamorelin stimulates natural growth .... Users should exercise extreme caution and adhere strictly to the intended use of such compoundsSupport Metabolic Health with SLU-PP-322 | Peptides at Elase.
The ongoing research into SLU-PP-332 continues to explore its full therapeutic potential. Scientists are investigating its efficacy in various disease models, its long-term effects, and its synergistic potential when combined with other therapeutic agents. As research progresses, a clearer picture of SLU-PP-332's benefits, limitations, and safety will emerge, potentially paving the way for future clinical applications. The peptide represents a significant advancement in understanding how to pharmacologically mimic the beneficial effects of exercise, offering hope for novel strategies in combating metabolic diseases and improving overall health.
Join the newsletter to receive news, updates, new products and freebies in your inbox.